Capricor Reports Slower Disease Progression in 4-Year Duchenne Study
MT Newswires Live
Jun 20
Capricor Therapeutics (CAPR) reported positive four-year data from its ongoing open-label extension trial of Deramiocel for Duchenne muscular dystrophy, showing reduced skeletal muscle disease progression and continued safety.
Patients experienced a median change of -0.5 points from baseline, suggesting that extended treatment with Deramiocel may help slow the disease progression over time, the company said Friday in a statement.
The therapy maintained a "favorable safety profile," the company said.
Despite the positive data, the company's shares fell 17% in recent Friday trading, paring earlier losses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.